Ovranette is a monophasic 21-day contraceptive pill containing the active ingredients ethinylestradiol and levonorgestrel. It helps to make it harder for the sperm to penetrate the womb and to reduce the chance of a fertilised egg implanting in the womb. It is over 99% effective at preventing pregnancy if taken correctly.
Ovranette is a prescription only medicine, like any other prescription medication you must consult a doctor before using it.
Private Doc offers a confidential free consultation service that may result in you receiving a prescription for Ovranette if it is deemed appropriate and can prescribed safely.
Complete a 100% free and secure consultation to explore your treatment options.
Who can take Ovranette
Private Doc will prescribe a 3-month supply of Ovranette contraceptive pill to women where Ovranette is suitable. Women qualify for Ovranette if:
- They have been taking Ovranette for the last year.
- They have had no problems with Ovranette in the last year.
- They have had a face-to-face pill check-up for their contraceptive pill in the last year.
How to take Ovranette
Take Ovranette every day for 21 days
- Ovranette comes in strips of 21 pills, each marked with a day of the week.
- Take your pill at the same time every day.
- Start by taking a pill marked with the correct day of the week.
- Follow the direction of the arrows on the strip. Take one pill each day, until you have finished all 21 pills
- Then have a 7-day break when you will have your period.
- Following the 7-day pill-free period start your new pack of pills on the 8th day.
- Note - Swallow each pill whole, with water if necessary.
Do not take Ovranette if you:
Breastfeeding: <6 weeks postpartum
• History of confirmed venous thromboembolism (VTE). Known risk factors for VTE.
• Arterial thrombotic disorders (Cerebrovascular accident or coronary artery disease) or a history of these conditions, or prodromal conditions (e.g. angina pectoris and transient ischaemic attack)
• Smoking in women aged ≥35 years who smoke ≥15 cigarettes per day
• Severe or uncontrolled hypertension
• Known thrombogenic mutations, thrombogenic valvulopathies or congenital heart disease
• History of migraine with focal neurological symptoms
• Diabetes mellitus with vascular involvement
• Systemic Lupus Erythematosus (SLE) with positive (or unknown) antiphospholipid antibodies
• The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication
• Acute or severe chronic liver diseases, current or previous, as long as liver function values have not returned to normal
• Presence or history of liver tumours (benign or malignant)
• Known or suspected carcinoma of the breast or other known or suspected estrogen-dependent neoplasia
• Undiagnosed vaginal bleeding
• Hypersensitivity to the active substances